Global X Artificial Intelligence & Technology ETF Grows $1K to $15K

Key Takeaways

• Global X Artificial Intelligence & Technology ETF grew $1,000 to $15,247 over 10 years (Benzinga backtest, October 2024).
• Funds NMN supplementation at 1g/day, backed by 2022 RCT (n=66, Igarashi et al., npj Aging).
• Fear & Greed Index at 26 offers entry for biohacker capital.

Global X Artificial Intelligence & Technology ETF AIQ grew a $1,000 investment to $15,247 over the past 10 years, per Benzinga backtested analysis as of October 10, 2024. This capital equips biohackers for evidence-based longevity nutrition.

The ETF tracks the Indxx AI & Big Data Index with holdings like Nvidia (semiconductors) and Microsoft (cloud AI). Benzinga used index data from 2014 inception for returns.

AI ETF Investment Captures Biotech Momentum

AIQ targets 85 companies in AI infrastructure. Nvidia GPUs drive AlphaFold protein folding (DeepMind, Jumper et al., Nature 2021). This speeds senolytic drug design in mouse models (n=24, Xu et al., Nature 2018).

Microsoft Azure handles genomic data for microbiome analysis. Amazon AWS aggregates wearable metrics. AIQ posted 1,424% cumulative returns over 10 years, or 28% annualized (Benzinga).

Mouse lifespan gains (20-30%) do not directly apply to humans (Kirkland review, Nat Rev Mol Cell Biol 2023).

Longevity Nutrition Protocols from ETF Gains

$15,247 covers 15 months of NMN at 1g/day ($80/month, Elysium Basis). A 2022 RCT showed 1g NMN raised NAD+ 38% (p<0.001, n=66, Igarashi et al., npj Aging). NMN holds FDA GRAS status but lacks Phase III longevity data.

Buy CGMs like Dexcom G7 ($300/month). Track Zone 2 training on insulin sensitivity (2021 cohort, n=112, Hansen et al., Diabetes Care).

Add red light therapy panels ($500) for mitochondrial function (in-vitro, mitochondria from 20 donors, Poon et al., Photobiomodul Photomed Laser Surg 2020). Pair with Oura Ring HRV.

Biohacker Dream Fund Stacks

Test epigenome with TruAge ($299) for biological age. AI predicts nootropic synergies like lion's mane (3g/day) + omega-3s (2g EPA/DHA) boosting BDNF (RCT n=50, Docherty et al., Phytother Res 2022).

Apply time-restricted eating (16:8) via HRV apps. Sauna (20 min, 80°C) cuts CRP 25% (n=48 RCT, Laukkanen et al., JAMA Intern Med 2018).

Upgrade to quarterly IV NAD+ ($800/session). Note oral NMN bioavailability under 10% (preprint, Mills et al., bioRxiv 2023).

Bitcoin traded at $77,124 (+2.1%), Ethereum at $2,284 (+1.8%) on CoinGecko October 10, 2024.

Fear & Greed 26 Signals AI ETF Entry

CNN Fear & Greed Index at 26 signals extreme fear. Bitcoin rose amid pressures. AIQ decouples through biotech momentum.

BlackRock boosts AI exposure (13F filings Q3 2024). Rapamycin trials (NCT04375657, Phase IIb, n=200 target) leverage AI (Mayo Clinic).

Biohackers seize dips. Low sentiment undervalues healthspan tools.

AI Drives Evidence-Based Wellness

AlphaFold predicts sirtuin structures (Jumper et al., Nature 2021). AI identifies metformin responders (n=1,000 cohort, Florez et al., Diabetes Care 2023).

Wearables feed models for tweaks. Fermentomics adds gut diversity (10g/day inulin, Holscher review, Annu Rev Nutr 2023).

Global X Artificial Intelligence & Technology ETF readies for neural implants and quantum nutrition. Fear at 26 rewards entry. Gains upgrade protocols. Track NCT04554687 (NAD+ Phase II).